PXS-4728 by Syntara for Sleep Disorders: Likelihood of Approval

PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.

Biotest increases sales in the first half of 2024 by 35% to Euro 372 million – Biotech Investments

EQS-News: Biotest AG / Key word(s): Half Year Results/Half Year Results Biotest increases sales in the first half of 2024 by 35% to Euro 372

July 31, 2024

Marty Makary, often wrong as pandemic critic, is poised to lead the FDA he railed against

Panelists at a covid conference last fall were asked to voice their regrets — policies they had supported during the pandemic but had come to

March 7, 2025

Study finds tree nuts as snack alternative boost metabolic health in young adults

Study found that replacing typical carbohydrate snacks with tree nuts in young adults’ diets for 16 weeks improves metabolic health, with females showing reduced waist

December 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.